Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2026Small

Collagenase‐Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

SCShihong ChengPLPingping LuoHCHuirong Chi

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved lung function in pulmonary fibrosis models using collagenase-coated nanoparticles, indicating new treatment pathways.

Key Points

  • This research aims to develop a novel delivery system targeting fibroblast activity in pulmonary fibrosis.
  • Engineered collagenase-coated polymeric nanoparticles loaded with PDK1 siRNA for targeted delivery.
  • Administered via inhalation to murine models of pulmonary fibrosis to assess therapeutic effects.
  • Evaluated pharmacodynamics focusing on myofibroblast accumulation and collagen deposition.
  • PPLFazo/siPDK1@G-CLG reduced myofibroblast accumulation in murine models by 40%, P<0.05.
  • Significantly decreased collagen deposition in lungs, measured at a 30% reduction, P<0.01.
  • Demonstrated substantial reduction in abnormal fibrotic tissue growth, improving respiratory function in models.

Cite This Study

Cheng et al. (2026) studied this question.

synapsesocial.com/papers/6a49f5d7f5d1d45b288008a9https://doi.org/10.1002/smll.202512872
View Full Paper
Ask AI
Bookmark
Share